RecruitingPhase 2NCT06947993
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Sponsor
Novartis Pharmaceuticals
Enrollment
224 participants
Start Date
May 16, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).
Eligibility
Min Age: 18 YearsMax Age: 100 Years
Inclusion Criteria3
- Able and willing to sign the informed consent (IC)
- Patients with a diagnosis of AD and onset of disease for at least 1 year
- Moderate to severe AD
Exclusion Criteria5
- Participants with a clinically significant medical condition or infectious disease (specified in sub-protocol)
- Participants with clinically significant abnormal hematology, clinical chemistry, or urine test results or clinically significant abnormal ECG
- Participant with any other active inflammatory skin disease
- Participants with any chronic, uncontrolled medical condition, which would put the participant at increased risk during the study (e.g., uncontrolled: diabetes, hypertension)
- Participants with any clinically unstable disease states that would likely require systemic corticosteroids (e.g., uncontrolled asthma)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGGHZ339
GHZ339 administered at dose A, B, C and D
DRUGPlacebo
Matching placebo
Locations(99)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06947993
Related Trials
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
NCT072629831 location
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
NCT0700342545 locations
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
NCT0729080343 locations
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
NCT0727766050 locations
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
NCT050422581 location